Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.92 Billion KRW | -2.82% |
| 2022 | 7.97 Billion KRW | 1081.74% |
| 2021 | -811.82 Million KRW | -126.59% |
| 2020 | 3.05 Billion KRW | -11.96% |
| 2019 | 3.46 Billion KRW | 230.51% |
| 2018 | -2.65 Billion KRW | -232.12% |
| 2017 | 2.01 Billion KRW | -13.71% |
| 2016 | 2.33 Billion KRW | 36.56% |
| 2015 | 1.7 Billion KRW | -24.26% |
| 2014 | 2.25 Billion KRW | 3.01% |
| 2013 | 2.18 Billion KRW | 150.64% |
| 2012 | -4.31 Billion KRW | -215.2% |
| 2011 | 3.74 Billion KRW | 244.42% |
| 2010 | 1.08 Billion KRW | -63.17% |
| 2009 | 2.95 Billion KRW | -30.31% |
| 2008 | 4.24 Billion KRW | -37.65% |
| 2007 | 6.8 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.42 Billion KRW | 22.79% |
| 2024 Q3 | -407.74 Million KRW | -128.55% |
| 2024 Q1 | 1.16 Billion KRW | 382.36% |
| 2023 Q3 | 2.23 Billion KRW | -36.63% |
| 2023 Q2 | 3.52 Billion KRW | 47.21% |
| 2023 Q1 | 2.39 Billion KRW | 556.41% |
| 2023 Q4 | -411.98 Million KRW | -118.43% |
| 2023 FY | 7.74 Billion KRW | -2.82% |
| 2022 Q3 | 3.32 Billion KRW | 28.16% |
| 2022 FY | 7.97 Billion KRW | 1081.74% |
| 2022 Q4 | -524.89 Million KRW | -115.79% |
| 2022 Q2 | 2.59 Billion KRW | 0.64% |
| 2022 Q1 | 2.57 Billion KRW | 180.1% |
| 2021 Q2 | 487.17 Million KRW | 146.3% |
| 2021 Q3 | 2.21 Billion KRW | 353.7% |
| 2021 Q1 | -1.05 Billion KRW | -316.17% |
| 2021 FY | -811.82 Million KRW | -126.59% |
| 2021 Q4 | -3.21 Billion KRW | -245.56% |
| 2020 Q1 | 278.3 Million KRW | -64.36% |
| 2020 Q4 | -252.81 Million KRW | 65.53% |
| 2020 Q2 | 3.75 Billion KRW | 1250.23% |
| 2020 Q3 | -733.35 Million KRW | -119.52% |
| 2020 FY | 3.05 Billion KRW | -11.96% |
| 2019 Q3 | 471.87 Million KRW | 19.27% |
| 2019 FY | 3.46 Billion KRW | 230.51% |
| 2019 Q2 | 395.61 Million KRW | 0.29% |
| 2019 Q4 | 780.95 Million KRW | 65.5% |
| 2019 Q1 | 394.46 Million KRW | 109.58% |
| 2018 Q1 | 367.68 Million KRW | 451.27% |
| 2018 Q2 | 515.89 Million KRW | 40.31% |
| 2018 Q3 | 577.17 Million KRW | 11.88% |
| 2018 FY | -2.65 Billion KRW | -232.12% |
| 2018 Q4 | -4.11 Billion KRW | -813.43% |
| 2017 FY | 2.01 Billion KRW | -13.71% |
| 2017 Q4 | -104.67 Million KRW | -119.69% |
| 2017 Q3 | 531.66 Million KRW | -29.93% |
| 2017 Q2 | 758.71 Million KRW | -8.07% |
| 2017 Q1 | 825.27 Million KRW | 174.61% |
| 2016 Q1 | 1.19 Billion KRW | 302.14% |
| 2016 Q2 | -35.29 Million KRW | -102.94% |
| 2016 Q4 | 300.52 Million KRW | -65.29% |
| 2016 Q3 | 865.82 Million KRW | 2552.96% |
| 2016 FY | 2.33 Billion KRW | 36.56% |
| 2015 Q1 | 880.2 Million KRW | 34.0% |
| 2015 FY | 1.7 Billion KRW | -24.26% |
| 2015 Q4 | 298.05 Million KRW | 166.94% |
| 2015 Q3 | 111.65 Million KRW | -73.26% |
| 2015 Q2 | 417.56 Million KRW | -52.56% |
| 2014 Q2 | 398.16 Million KRW | -33.79% |
| 2014 Q1 | 601.38 Million KRW | 41.64% |
| 2014 Q4 | 656.89 Million KRW | 12.56% |
| 2014 FY | 2.25 Billion KRW | 3.01% |
| 2014 Q3 | 583.57 Million KRW | 46.57% |
| 2013 Q1 | 366.46 Million KRW | 127.29% |
| 2013 Q2 | 601.3 Million KRW | 64.08% |
| 2013 Q3 | 794.76 Million KRW | 32.17% |
| 2013 Q4 | 424.58 Million KRW | -46.58% |
| 2013 FY | 2.18 Billion KRW | 150.64% |
| 2012 Q3 | -651.08 Million KRW | 80.32% |
| 2012 FY | -4.31 Billion KRW | -215.2% |
| 2012 Q1 | 476.47 Million KRW | -78.49% |
| 2012 Q2 | -3.3 Billion KRW | -794.38% |
| 2012 Q4 | -1.34 Billion KRW | -106.27% |
| 2011 FY | 3.74 Billion KRW | 244.42% |
| 2011 Q1 | 1.36 Billion KRW | 2016.16% |
| 2011 Q2 | 421.28 Million KRW | -69.06% |
| 2011 Q3 | -248.74 Million KRW | -159.04% |
| 2011 Q4 | 2.21 Billion KRW | 990.46% |
| 2010 Q3 | -585.99 Million KRW | -175.05% |
| 2010 Q1 | 964.79 Million KRW | -55.26% |
| 2010 Q4 | -71.05 Million KRW | 87.87% |
| 2010 FY | 1.08 Billion KRW | -63.17% |
| 2010 Q2 | 780.77 Million KRW | -19.07% |
| 2009 FY | 2.95 Billion KRW | -30.31% |
| 2009 Q4 | 2.15 Billion KRW | 366.0% |
| 2009 Q3 | 462.76 Million KRW | 478.16% |
| 2009 Q2 | -122.37 Million KRW | -127.37% |
| 2009 Q1 | 447.02 Million KRW | 299.78% |
| 2008 Q3 | -1.73 Billion KRW | -151.61% |
| 2008 Q4 | -223.76 Million KRW | 87.12% |
| 2008 Q2 | 3.36 Billion KRW | 19.6% |
| 2008 Q1 | 2.81 Billion KRW | 12.83% |
| 2008 FY | 4.24 Billion KRW | -37.65% |
| 2007 Q2 | 2.93 Billion KRW | 6.38% |
| 2007 FY | 6.8 Billion KRW | 0.0% |
| 2007 Q3 | -1.38 Billion KRW | -147.12% |
| 2007 Q4 | 2.49 Billion KRW | 280.4% |
| 2007 Q1 | 2.75 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1800.199% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 90.99% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 108.706% |
| HANDOK Inc. | 12.57 Billion KRW | 44.932% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 448.237% |
| Yuhan Corporation | 74.56 Billion KRW | 90.71% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 38.033% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 138.392% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 96.92% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -126.662% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 51.73% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -1061.452% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -618.736% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 74.375% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1800.199% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 189.31% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -71.729% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 109.903% |
| JW Holdings Corporation | 143.66 Billion KRW | 95.178% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 112.968% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 97.191% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.094% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 114.616% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -7.045% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 20.666% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1800.199% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 85.796% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 94.808% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.094% |
| Yuhan Corporation | 74.56 Billion KRW | 90.71% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 66.889% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -122.203% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 83.889% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 93.094% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 66.184% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 87.394% |
| CKD Bio Corp. | -20.15 Billion KRW | 134.373% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 78.51% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 72.623% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 78.703% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 114.616% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 79.102% |
| Boryung Corporation | 68.26 Billion KRW | 89.853% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 118.473% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 51.73% |
| JW Lifescience Corporation | 32.09 Billion KRW | 78.415% |